• Small Molecules Improve Pancreatic Ductal Organoids

  2026-10-09

  Liao and colleagues describe a small-molecule culture strategy that improves the initiation and expansion of pancreatic ductal organoids while retaining heterogeneous ductal and acinar features. The study provides a more scalable conceptual platform for pancreatic disease modeling and drug-screening research, although the supplied report does not establish how each compound contributes to the phenotype.

• β-Elemene Inhibits Adipogenesis via AMPK

  2026-10-09

  A 2025 study reports that β-Elemene reduces differentiation-associated lipid accumulation and improves glucose handling in 3T3-L1 cellular models, with AMPK signaling identified as a responsive pathway. The work provides a mechanistic starting point for metabolic research, but its findings remain limited to an in vitro mouse preadipocyte system and do not establish efficacy in obesity, diabetes, or human disease.

• CS18, TopBP1, and Therapeutic Resistance

  2026-10-08

  Lin and colleagues report CS18, a structurally distinct inhibitor of the TopBP1 BRCT7/8 domains that disrupts oncogenic protein interactions without directly interfering with DNA replication. The study links CS18 to MYC suppression, E2F1-dependent apoptosis, PARP inhibitor sensitization, and restored osimertinib response in preclinical cancer models.

• Ibuprofen in Research: Evidence and Limits

  2026-10-08

  A source-grounded overview of Ibuprofen research, covering COX biology, cancer and pain models, conceptual applications, evidence quality, protein-binding context, and limits on interpreting vendor-reported findings.

• Streptavidin-FITC and PFOS Sertoli Cell Research

  2026-10-07

  A source-grounded overview of PFOS-related Sertoli-cell injury, the ATF2/WT1 mitochondrial mechanism, and the conceptual role and limits of Streptavidin-FITC detection.

• Human iPSC Sensory Neurons Model HSV-1 Latency

  2026-10-07

  Oh et al. developed and validated a scalable human induced pluripotent stem cell-derived sensory neuron model for studying HSV-1 latency and reactivation. The model combines neuronal functional validation with virological, transcriptional, and chromatin-based evidence, offering a human-relevant complement to animal systems while retaining important in vitro limitations.

• SB 431542 in TGF-β and Intestinal Research

  2026-10-06

  SB 431542 is an ALK5 inhibitor used to investigate TGF-β signaling. In a mouse study of intestinal MOB1A/B depletion, pharmacologic pathway inhibition partially restored epithelial differentiation but did not recover intestinal stem-cell pools, highlighting both the value and limits of pathway-level interpretation.

• How O-GlcNAcylation Rewires Wnt-Driven Bone Formation

  2026-10-06

  A 2024 EMBO Reports study identifies O-GlcNAcylation as a mechanistic link between Wnt signaling, aerobic glycolysis, and osteoblast formation. Its findings place PDK1 modification and stabilization downstream of a temporally distinct Ca2+-PKA-GFAT1 response and provide a framework for interpreting cAMP signaling pathway modulation in bone biology.

• Optimized hiPSC Platelet Differentiation: Study Analysis

  2026-10-05

  Yue and colleagues report an optimized differentiation scheme that improves megakaryocyte generation and functional platelet output from human induced pluripotent stem cells. The study combines changes in cellular input, culture composition, cytokine replacement, and megakaryocyte maturation, while reporting a 19-day workflow, 14.9 platelets per iPSC, and a 58.3% cost reduction.

• Crizotinib in Gastric Cancer Assembloid Research

  2026-10-05

  This overview examines the research rationale for studying Crizotinib hydrochloride in patient-derived gastric cancer assembloids. It separates supplier-reported target information from peer-reviewed findings, compares organoid and assembloid evidence, and outlines relevant applications, uncertainties, and translational boundaries without presenting experimental procedures.

• 3-Bromopyruvate, Autophagy, and Cetuximab Resistance

  2026-10-04

  A 2023 Cancer Gene Therapy study reports that 3-bromopyruvate combined with cetuximab produced synergistic antiproliferative effects in colorectal cancer models resistant to cetuximab. The authors link this response to FOXO3a-centered activation of autophagy, ferroptosis, and apoptosis, while the preclinical design leaves important questions about clinical transferability and pathway dependence.

• Alkaline Phosphatase Substrate Test Kit Overview

  2026-10-03

  The Alkaline Phosphatase (AP) Substrate Test Kit, SKU K4151, is an APExBIO-supplied BCIP/NBT chromogenic product described for visual alkaline phosphatase activity detection. No matched paper evidence was available, so performance and application-specific suitability remain unverified.

• Regorafenib Reduces RRM2 in Melanoma

  2026-10-02

  The 2024 iScience study identifies RRM2 as a mechanistically important downstream target of Regorafenib in melanoma, linking multikinase inhibition to ERK/E2F3 signaling, reduced malignant behavior, and apoptosis. Its cell-based, transcriptomic, rescue, and in vivo experiments provide a framework for studying Regorafenib beyond angiogenesis and for designing more mechanism-resolved cancer biology research workflows.

• Rocket-Like Nanomedicine Restores PDAC Stroma

  2026-10-01

  The 2026 Materials Today Bio study developed an acid-responsive, sequential-release nanomedicine that combines stromal remodeling with gemcitabine delivery for pancreatic ductal adenocarcinoma. Its key contribution is a homeostasis-restoring strategy using Halofuginone and the uPAR–uPA axis inhibitor IPR-803 to improve drug penetration and suppress tumor growth in vivo.

• LDN-193189 ALK Inhibitor Workflow for BMP Studies

  2026-10-01

  LDN-193189 provides a focused way to test how ALK2/ALK3-driven BMP signaling reshapes epithelial differentiation, Smad activity, and barrier phenotypes. This workflow translates intestinal evidence into practical cell-based assays while highlighting solubility controls, endpoint selection, and model-specific limitations.

8084 records 1/539 page Next 12345 下5页 Last page